IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL

被引：0

作者：

Doerner, T. ^{[1
]}

Bowman, S. J. ^{[2
]}

Fox, R. ^{[3
]}

Mariette, X. ^{[4
]}

Papas, A. ^{[5
]}

Grader-Beck, T. ^{[6
]}

Fisher, B. A. ^{[2
]}

Barcelos, F. ^{[7
]}

De Vita, S. ^{[8
]}

Schulze-Koops, H. ^{[9
]}

Moots, R. J. ^{[10
]}

Junge, G. ^{[11
]}

Woznicki, J. ^{[12
]}

Sopala, M. ^{[11
]}

Luo, W. ^{[12
]}

Hueber, W. ^{[11
]}

机构：

[1] Charite, Dept Med Rheumatol & Clin Immunol, Berlin, Germany

[2] Univ Hosp Birmingham NHS Fdn Trust, Dept Rheumatol, Birmingham, England

[3] Scripps Mem Hosp & Res Inst, La Jolla, CA USA

[4] Univ Paris Saclay, Paris, France

[5] Tufts Sch Dent Med, Div Oral Med, Boston, MA USA

[6] Johns Hopkins Sch Med, Div Rheumatol, Baltimore, MD USA

[7] Inst Portugues Reumatol, Lisbon, Portugal

[8] Univ Hosp Udine, Div Rheumatol, DAME, Udine, Italy

[9] Ludwig Maximilians Univ Munchen, Div Rheumatol & Clin Immunol, Munich, Germany

[10] Aintree Univ Hosp NHS Fdn Trust, Acad Rheumatol Dept, Liverpool, England

[11] Novartis Pharma AG, Basel, Switzerland

[12] Novartis Pharmaceut, E Hanover, NJ USA

来源：

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2022年 / 40卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

119

引用

下载

页码：87 / 88

页数：2

共 50 条

[21] A Phase 2B, Multicenter, Randomized, Placebo-Controlled Dose-Ranging Trial of Peficitinib, an Oral JAK Inhibitor, in Patients with Moderately-Severely Active UC
Sands, Bruce
Sandborn, William
Feagan, Brian
Lichtenstein, Gary
Zhang, Hongyan
Szapary, Philippe
Panes, Julian
Vermeire, Severine
Christopher, O. O'' Brien
Dewey, Julia
Yang, Zijiang
Johanns, Jewel
Strauss, Richard
Marano, Colleen
INFLAMMATORY BOWEL DISEASES, 2017, 23 : S8 - S8
[22] Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study
van der Heijde, Desiree
Gensler, Lianne
Deodhar, Atul
Baraliakos, Xenofon
Poddubnyy, Denis
Kivitz, Alan
Oortgiesen, Marga
Baeten, Dominique
Goldammer, Nadine
Coarse, Jason
Farmer, M. K.
Dougados, Maxime
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[23] Efficacy and safety of telitacicept in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial
Xu, Dong
Fang, Jianmin
Zhang, Shangzhu
Huang, Cibo
Huang, Chenghui
Qin, Li
Li, Xiaomei
Chen, Meiqing
Liu, Xiumei
Liu, Yi
Li, Zhijun
Hu, Jiankang
Bao, Chunde
Wei, Wei
Tian, Jing
Duan, Xinwang
Zeng, Xiaofeng
RHEUMATOLOGY, 2024, 63 (03) : 698 - 705
[24] Efficacy and Safety of Telitacicept in Primary Sjogren's Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial
Xu, Dong
Zhang, Shangzhu
Huang, Cibo
Huang, Chenghui
Qin, Li
Li, Xiaomei
Chen, Meiqing
Liu, Xiumei
Liu, Yi
Li, Zhijun
Hu, Jiankang
Bao, Chunde
Wei, Wei
Tian, Jing
Duan, Xinwang
Fang, Jianmin
Zeng, Xiaofeng
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4002 - 4004
[25] The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
Emery, P
Fleischmann, R
Filipowicz-Sosnowska, A
Schechtman, J
Szczepanski, L
Kavanaugh, A
Racewicz, AJ
Van Vollenhoven, RF
Li, NF
Agarwal, S
Hessey, EW
Shaw, TM
ARTHRITIS AND RHEUMATISM, 2006, 54 (05): : 1390 - 1400
[26] Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
Stohl, William
Merrill, Joan T.
McKay, James D.
Lisse, Jeffrey R.
Zhong, Z. John
Freimuth, William W.
Genovese, Mark C.
JOURNAL OF RHEUMATOLOGY, 2013, 40 (05) : 579 - 589
[27] EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
Van der Heijde, D.
Gensler, L. S.
Deodhar, A.
Baraliakos, X.
Poddubnyy, D.
Kivitz, A.
Farmer, M. K.
Baeten, D.
Goldammer, N.
Coarse, J.
Oortgiesen, M.
Dougados, M.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 68 - 69
[28] Efficacy and Safety of Oral Tofacitinib for Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial
D'Haens, Geert R.
Panaccione, Remo
Higgins, Peter
Colombel, Jean-Frederic
Feagan, Brian G.
Moscariello, Michele
Chan, Gary
Healey, Paul J.
Niezychowski, Wojciech
Wang, Wenjin
Marren, Amy
Maller, Eric
GASTROENTEROLOGY, 2016, 150 (04) : S183 - S183
[29] Efficacy and safety of abatacept in active primary Sjogren's syndrome: results of a phase III, randomised, placebo-controlled trial
Baer, Alan N.
Gottenberg, Jacques-Eric
St Clair, E. William
Sumida, Takayuki
Takeuchi, Tsutomu
Seror, Raphaele
Foulks, Gary
Nys, Marleen
Mukherjee, Sumanta
Wong, Robert
Ray, Neelanjana
Bootsma, Hendrika
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (03) : 339 - 348
[30] EFFICACY AND SAFETY OF ABATACEPT IN ACTIVE PRIMARY SJOGREN'S SYNDROME: RESULTS OF A RANDOMISED PLACEBO-CONTROLLED PHASE III TRIAL
Baer, Alan
Gottenberg, Jacques-Eric
St Clair E, William
Sumida, Takayuki
Takeuchi, Tsutomu
Seror, Raphaele
Foulks, Gary
Nys, Marleen
Johnsen, Alyssa
Wong, Robert
Ray, Neelanjana
Bootsma, Hendrika
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 89 - 90

← 1 2 3 4 5 →